ENTEROME
Enterome is an integrated company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics.Enterome is focused on the identification of the bioactive molecules that are differentially expressed, secreted and regulated by the gut microbiome, which play a central role in the regulation of key aspects of human physiology and the immune system.
ENTEROME
Industry:
Biopharma Biotechnology Health Care Life Science
Founded:
2011-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.enterome.com
Total Employee:
11+
Status:
Active
Contact:
33 1 76 21 58 19
Email Addresses:
[email protected]
Total Funding:
128.91 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Content Delivery Network
Similar Organizations
EnteroBiotix
EnteroBiotix is a developer of novel medicinal products intended to restore health and prevent bacterial infections.
Current Advisors List
Current Employees Featured
Founder
Investors List
Seventure Partners
Seventure Partners investment in Series E - ENTEROME
Principia SGR
Principia SGR investment in Series E - ENTEROME
Nestlé Health Science
Nestlé Health Science investment in Series E - ENTEROME
Omnes Capital
Omnes Capital investment in Series E - ENTEROME
Health for Life Capital fund
Health for Life Capital fund investment in Series E - ENTEROME
Takeda
Takeda investment in Series E - ENTEROME
Lundbeckfonden Ventures
Lundbeckfonden Ventures investment in Debt Financing - ENTEROME
Principia SGR
Principia SGR investment in Debt Financing - ENTEROME
Nestlé Health Science
Nestlé Health Science investment in Debt Financing - ENTEROME
Seventure Partners
Seventure Partners investment in Debt Financing - ENTEROME
Official Site Inspections
http://www.enterome.com Semrush global rank: 2.13 M Semrush visits lastest month: 9.49 K
- Host name: 217-160-0-215.elastic-ssl.ui-r.com
- IP address: 217.160.0.215
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "ENTEROME"
Enterome
Enterome’s potentially first-in-class drug candidates modulate the immune system by closely mimicking the structure, effect or actions of specific antigens, hormones or cytokines. The …See details»
ENTEROME - Crunchbase Company Profile & Funding
Enterome’s OncoMimic technology allows the overcoming of immune tolerance against cancer cells, with broad applicability against solid tumor via an off-the-shelf, easy to manufacture …See details»
Enterome | Leukemia and Lymphoma Society
Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, allowing it to analyze and uncover new biological insights …See details»
Enterome Company Profile 2024: Valuation, Funding & Investors
Enterome General Information Description. Developer of pharmaceuticals and diagnostics tests designed for developing off-the-shelf, transformational cancer treatments targeting all tumor …See details»
Enterome - LinkedIn
Enterome | 15,065 followers on LinkedIn. Delivering the promise of immunotherapy | Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the ...See details»
Careers - Enterome
Enterome achieved a score of 96/100!! Since 2018, companies with more than fifty employees are required to calculate and publish each year the gender equality index. For the year 2023, Enterome achieved a score of 96 points out …See details»
ENTEROME - Funding, Financials, Valuation & Investors
Enterome is a clinical-stage company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Search Crunchbase. ... How much funding has this …See details»
ENTEROME - Contacts, Employees, Board Members, Advisors
Organization. ENTEROME . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Contacts 6. About. ENTEROME has 7 current …See details»
Microbiome company Enterome plans $108m raise to …
Aug 25, 2023 On 14 June, the company announced early clinical data from the first cohort of the Phase I/II SIDNEY trial (NCT04669171), which studied E02463. Enterome has now started to recruit patients in the first expansion cohort, …See details»
ENTEROME Company Profile - Office Locations, Competitors
ENTEROME has 5 employees across 2 locations, $129.57 m in total funding, and €2.71 m in annual revenue in FY 2020. See insights on ENTEROME including office locations, …See details»
Enterome - Overview, News & Similar companies | ZoomInfo.com
Who is Enterome. Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer and im mune …See details»
Enterome Announces Successful Completion of Phase 2 ROSALIE …
Apr 17, 2024 Enterome’s first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect, or actions of specific antigens, …See details»
Enterome - Significant Progress with OncoMimics™ and …
Nov 4, 2021 • First clinical proof of concept data with lead OncoMimicsâ„¢ therapeutic cancer vaccine candidate EO2401 expected in H1 2022 • New Corporate Identity and Website …See details»
Enterome signs major strategic R&D collaboration with Nestlé …
Jul 18, 2022 About Enterome . Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer and immune …See details»
Enterome expands and strengthens its management team
Apr 3, 2019 Jan Fagerberg M.D., Ph.D. appointed Chief Medical Officer and Catherine Mathis, Pharm.D. appointed Chief Development Officer Paris, France and Cambridge, MA, USA – …See details»
Enterome - Significant Progress with OncoMimics™ and …
PARIS, Nov. 4, 2021 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its unique ability to decode the gut …See details»
Enterome announces sustained positive clinical outcomes
May 31, 2023 Enterome employs 70 people and is headquartered in Paris, France. Since its inception, the company has raised a total of €116 million from Europe- and US-based life …See details»
Enterome
Jul 18, 2022 Enterome and Nestlé Health Science will co-develop Enterome’s lead EndoMimicsâ„¢ compound, EB1010, a potent local inducer of IL-10 targeting food allergies and …See details»
Enterome
Enterome has developed a target-driven approach to drug discovery based on a unique and progressive understanding of the human gut microbiome and its effects on the immune …See details»